# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN
- Date: 2026-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Vivian Tolliver, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Nine-month HIV review: decision about stopping toxoplasmosis maintenance therapy. **S**

## History of present illness

Mr. Ashe returns nine months after his first visit, about thirteen months after starting antiretroviral therapy. He has missed no doses and has had no headache, weakness, seizure, rash, fever, or chest pain. His colonoscopy appointment is next month. He has read the result of the syphilis test from the preventive visit, which was sent to him by secure message. He has thought about anal cancer screening and would like to have it at his next visit. Today's blood tests were drawn this morning. **S**

| Element | Detail |
|---|---|
| Adherence | No missed doses |
| Symptoms | None |
| Screening | Colonoscopy booked; anal cancer screening chosen for the next visit |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; weight stable |
| Cardiovascular | Negative | No chest pain |
| Neurological | Negative | No headache, seizure, or weakness |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/74 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 75 kg; BMI 21.9 kg/m². All vital signs are synthetic.

HIV-1 viral load: 0 {copies}/mL; CD4 count: 318 /uL (low); White cell count: 5 10*3/uL; Hemoglobin: 14.1 g/dL; Platelets: 236 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.12 mg/dL; eGFR: 82 mL/min/1.73 m²; Glucose: 91 mg/dL. All results are synthetic.

## Change since baseline

- HIV-1 viral load: 42 {copies}/mL (high) at baseline, 0 {copies}/mL at this visit **S**
- CD4 count: 156 /uL (low) at baseline, 318 /uL (low) at this visit **S**
- White cell count: 4.2 10*3/uL at baseline, 5 10*3/uL at this visit **S**
- Hemoglobin: 13 g/dL (low) at baseline, 14.1 g/dL at this visit **S**
- Platelets: 198 10*3/uL at baseline, 236 10*3/uL at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.9 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 1.18 mg/dL at baseline, 1.12 mg/dL at this visit **S**
- eGFR: 78 mL/min/1.73 m² at baseline, 82 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 91 mg/dL at this visit **S**

## Immunizations given today

- Influenza vaccine, 2026-2027 season **S**
- COVID-19 vaccine, 2026-2027 formula **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 75.0 kg, blood pressure 120/74 |
| Mouth | No thrush |
| Neurological | No focal deficit; strength equal on both sides |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cerebral toxoplasmosis on maintenance therapy** (B58.2). All criteria for stopping maintenance are met: six weeks of acute treatment completed, no symptoms, viral load undetectable since three months, and CD4 above 200 for more than six months (218, 262, and now 318). The same counts allow Pneumocystis prophylaxis to stop. **S**
   - Stop trimethoprim-sulfamethoxazole today.
   - Restart it if the CD4 count falls below 200.
   - Report any headache, weakness, seizure, or fever the same day.
2. **HIV infection** (B20). Viral load not detected for the third time; CD4 318. Blood count normal: hemoglobin 14.1 g/dL, white cells 5.0, platelets 236. Potassium 4.5 mmol/L and creatinine 1.12 mg/dL. **S**
   - Continue the same regimen.
   - Viral load and CD4 count in three months, then every three to six months.
   - Influenza and COVID-19 vaccines today.
3. **Coronary artery disease after two bypass operations** (I25.10). No angina; blood pressure at goal. **S**
   - Yearly lipid panel at the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HIV-1 viral load | 4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 months | Completed today | Not detected (below 20 copies/mL), the third undetectable result |
| Laboratory | CD4 count | Every 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ART | Completed today | 318 cells/uL, above 200 for more than six months |
| Medication safety | ART adherence and drug-interaction review (antacids, calcium, iron, new medicines) | Every visit | Completed today | No missed doses; no interacting medicines |
| Laboratory | Complete blood count | Every 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ART | Completed today | Hemoglobin 14.1 g/dL, white cells 5.0, platelets 236 |
| Laboratory | Potassium, creatinine, and eGFR | 1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 months | Completed today | Potassium 4.5 mmol/L, creatinine 1.12 mg/dL, eGFR 82 |
| Laboratory | Urine albumin-to-creatinine ratio on tenofovir | At the start of tenofovir and yearly | Up to date | Normal three months ago; next in one year |
| Laboratory | ALT | Every 6 months on ART; with symptoms on a statin | Due | ALT 27 U/L six months ago; with the lipid panel at the next visit |
| Medication safety | Toxoplasma maintenance therapy and stopping criteria | Continue until CD4 above 200 for more than 6 months on ART with a suppressed viral load | Completed today | Criteria met; trimethoprim-sulfamethoxazole stopped today; restart if CD4 falls below 200 |
| Medication safety | Pneumocystis prophylaxis | While CD4 below 200; stop after more than 3 months above 200 | Completed today | CD4 above 200 for more than three months; prophylaxis stops with the maintenance dose |
| Examination | Neurological check: headache, seizure, weakness, and right-hand strength | Every visit | Completed today | No symptoms; same-day review if any develop |
| Laboratory | Syphilis screen | Yearly | Up to date | Drawn at the preventive visit; result reviewed with him; next in one year |
| Self-management | Influenza and COVID-19 vaccines | Each autumn | Completed today | Inactivated influenza vaccine and COVID-19 vaccine given today |
| Self-management | Psychosocial support, disclosure on his terms, and U=U counseling | Every visit | Completed today | Well supported; disclosure remains his decision |
| Survey | Depression screen (PHQ-9 or PHQ-2) | At intake, at six months, and yearly | Up to date | PHQ-2 0 two months ago |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 120/74 mmHg |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 75.0 kg, BMI 21.9; stable |
| Self-management | Tobacco use | Every visit | Completed today | Never used tobacco |
| Medication safety | Coronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibe | Every visit | Completed today | Taking all three |
| Self-management | Angina review and chest-pain plan | Every visit | Completed today | No angina |
| Laboratory | Lipid panel | 4 to 12 weeks after a change, then every 3 to 12 months; yearly when stable | Due | Yearly panel at the next visit |
| Imaging | Stress testing, coronary imaging, or echocardiography | Only with new or worsening symptoms; routine surveillance not recommended | Not indicated | No symptoms |

## Goal progress

- HIV-1 viral load not detected by the three-month visit. Outcome by 2026-04-13: Viral load not detected (below 20 copies/mL) at three months, and at six and nine months. **S**
- CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely. Outcome by 2026-10-19: CD4 218 at three months, 262 at six months, and 318 at nine months; trimethoprim-sulfamethoxazole stopped. **S**
- LDL cholesterol below 55 mg/dL by the three-month visit. Outcome by 2026-04-13: LDL cholesterol 52 mg/dL on atorvastatin and ezetimibe. **S**
- Hepatitis B vaccine series completed with a protective antibody level by the three-month visit. Outcome by 2026-04-13: Hepatitis B surface antibody 86 mIU/mL. **S**
- Keep blood pressure below 130/80 mmHg. Outcome by 2026-07-13: Blood pressure 116 to 120 over 72 to 74 at every visit. **S**

## Medication changes

- Stopped: Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily **S**

## Guideline basis

- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition), U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition), National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024), International Antiviral Society-USA (JAMA)
- Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020), HIV Medicine Association of the Infectious Diseases Society of America (Clinical Infectious Diseases)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- HIV review in three months with viral load, CD4 count, lipid panel, ALT, and anal cancer screening. Colonoscopy next month. Same-day visit for headache, weakness, seizure, or fever. **S**

